Show simple item record

dc.contributor.authorVasiliadou, I
dc.contributor.authorBreik, O
dc.contributor.authorBaker, H
dc.contributor.authorLeslie, I
dc.contributor.authorSim, VR
dc.contributor.authorHegarty, G
dc.contributor.authorMichaelidou, A
dc.contributor.authorNathan, K
dc.contributor.authorHartley, A
dc.contributor.authorGood, J
dc.contributor.authorSanghera, P
dc.contributor.authorFong, C
dc.contributor.authorUrbano, TG
dc.contributor.authorLei, M
dc.contributor.authorPetkar, I
dc.contributor.authorFerreira, MR
dc.contributor.authorNutting, C
dc.contributor.authorWong, KH
dc.contributor.authorNewbold, K
dc.contributor.authorHarrington, K
dc.contributor.authorBhide, S
dc.contributor.authorKong, A
dc.date.accessioned2021-04-20T13:36:31Z
dc.date.available2021-04-20T13:36:31Z
dc.date.issued2021-03-19
dc.identifier.citationCancers, 2021, 13 (6)
dc.identifier.issn2072-6694
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4526
dc.identifier.eissn2072-6694
dc.identifier.doi10.3390/cancers13061413
dc.description.abstractNivolumab is an anti-PD-1 monoclonal antibody currently used as immunotherapy for patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) with evidence of disease progression after platinum-based chemotherapy. This study evaluates real-world safety and treatment outcomes of non-trial nivolumab use. A retrospective multicenter cohort study of patients with recurrent/metastatic HNSCC treated with nivolumab between January 2017 and March 2020 was performed. Overall, 123 patients were included. The median age was 64 years, the majority of patients were male (80.5%) and had a smoking history (69.9%). Primary outcomes included overall response rate (ORR) of 19.3%, median progression-free survival (PFS) of 3.9 months, 1-year PFS rate of 16.8%, a median overall survival (OS) of 6.5 months and 1-year OS rate of 28.6%. These results are comparable to the CHECKMATE-141 study. Of 27 patients who had PD-L1 status tested, positive PD-L1 status did not significantly affect PFS ( p = 0.86) or OS ( p = 0.84). Nivolumab was well tolerated with only 15.1% experiencing immune-related toxicities (IRT) and only 6.7% of patients stopping due to toxicity. The occurrence of IRT appeared to significantly affect PFS ( p = 0.01) but not OS ( p = 0.07). Nivolumab in recurrent/metastatic HNSCC is well tolerated and may be more efficacious in patients who develop IRT.
dc.formatElectronic
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleSafety and Treatment Outcomes of Nivolumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Retrospective Multicenter Cohort Study.
dc.typeJournal Article
dcterms.dateAccepted2021-03-15
rioxxterms.versionVoR
rioxxterms.versionofrecord10.3390/cancers13061413
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2021-03-19
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfCancers
pubs.issue6
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.publication-statusPublished
pubs.volume13
pubs.embargo.termsNot known
icr.researchteamTargeted Therapy
icr.researchteamTargeted Therapyen_US
dc.contributor.icrauthorHarrington, Kevinen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0